Back to top

Biogen (NASDAQ:BIIB) Shows Strong Technical Breakout Setup With Perfect Trend Rating

The Technical Breakout Setups screen is built on a simple premise: the best trading opportunities come from stocks that combine a strong technical trend with a well-defined chart pattern. A recent run of that screen surfaced BIOGEN INC (NASDAQ:BIIB), a biopharmaceutical company focused on neurological and neurodegenerative diseases, as a name currently checking both boxes.

BIOGEN INC stock chart

Technical strength first

The ChartMill Technical Rating is designed to measure the overall health of a stock's trend across multiple time frames. It takes into account relative strength, moving averages, and the evolution of price action over both the short and long term. Biogen currently scores a perfect 10, well above the screen's minimum requirement of 7. That rating is supported by positive short term and long term trends, with the price trading above rising 20, 50, 100, and 200 day moving averages.

The stock is also showing solid liquidity, with an average daily volume of more than 1.2 million shares. One thing to keep in mind is that while Biogen is trading in the upper part of its 52 week range, the S&P 500 is near a new high, meaning the stock is slightly lagging the broader market at this point. That is worth monitoring, but it does not undermine the positive internal trend.

Investors who want to review the full technical picture can do so in the technical analysis report.

Setup quality and the breakout pattern

A high technical rating alone is not enough to define a good trade. If a stock has run too far too fast, it may be extended and difficult to enter with a reasonable stop. That is why the Technical Breakout Setups screen also requires a strong Setup Quality Rating. This score looks at whether a stock is forming a base, with prices trading in a tight range, volatility decreasing, and support located just below the current price.

Biogen scores a 9 on the setup scale. The setup summary points to recent consolidation, reduced volatility, and very little resistance above the current price. A support zone below the stock gives traders a clear area to place a stop loss. In addition, the Effective Volume indicator has detected large player activity in the last few days, which is a bonus often associated with institutional buying.

Key technical and setup metrics

  • Technical Rating: 10
  • Setup Rating: 9
  • 12-month performance: +51.4%
  • Relative strength: 85.88
  • Average daily volume: ~1.23 million shares
  • Proposed entry: $215.61
  • Proposed stop: $202.37
  • Worst-case loss from entry: 6.14%
  • Average true range: $6.49, or 2.95% of price

The proposed entry sits just above the 10-day high, so a buy stop order would only trigger on a confirmed breakout. The stop loss sits below the identified support zone, which keeps the worst-case loss defined at 6.14% if the trade does not work out.

Why this combination matters

The logic behind the Technical Breakout Setups screen is that a trade has a much higher chance of succeeding when both the trend and the pattern are in sync. A technically strong stock that is still forming a tight base offers two advantages: the trend provides the tailwind, while the setup provides a controlled entry point and a logical place to cut losses. Biogen ticks both boxes. The perfect technical rating places it among the strongest stocks in the market, and the high setup rating suggests it has built enough of a consolidation zone to support a breakout attempt.

Traders should always remember that a setup is not a guarantee. Stops and position sizing are still required, and upcoming news or earnings events should be checked before entering any trade.

Investors who want to apply this same methodology to the broader market can find more stocks currently matching the technical and setup criteria in the Technical Breakout Setups screen.

Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Biogen Inc. (BIIB)